rimegepant
Selected indexed studies
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. (Lancet, 2021) [PMID:33338437]
- Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. (CNS Drugs, 2023) [PMID:36739335]
- Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. (N Engl J Med, 2019) [PMID:31291516]
_Worker-drafted node — pending editorial review._
Connections
rimegepant is a side effect of
Sources
- Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. (2024) pubmed
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. (2021) pubmed
- Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. (2023) pubmed
- Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. (2019) pubmed
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. (2019) pubmed
- Rimegepant. (2012) pubmed
- Rimegepant. (2006) pubmed
- Rimegepant for migraine. (2024) pubmed
- Rimegepant: First Approval. (2020) pubmed
- PMID:40198022 (2023) pubmed